Phase 3 sweep across all endpoints positions QTORIN rapamycin for first approval in microcystic LMs — if FDA accepts single-pivotal-trial NDA on novel disease-specific endpoints

Bull

FDA approves QTORIN rapamycin based on the SELVA Phase 3 data, accepting the mLM-IGA and mLM-MCSS as novel, fit-for-purpose endpoints in a single-pivotal-trial NDA — a win that would establish Palvella as the only company with an approved pharmacotherapy for microcystic LMs. Approval would unlock orphan drug exclusivity, enable commercial launch in a disease with no approved standard of care, and de-risk the broader QTORIN platform by demonstrating the regulatory model works for subsequent indications including cutaneous venous malformations and angiokeratomas.

Bear

The most likely failure modes are FDA declining to accept the novel disease-specific endpoints (mLM-IGA, mLM-MCSS) as adequate evidence of clinical benefit, or the agency requiring an additional controlled trial before granting approval — both of which would delay or derail the single-pivotal-trial NDA strategy that is core to the thesis. A Complete Response Letter citing inadequate endpoint validation, small sample size in key subgroups (e.g., n=13 in the 6–11 cohort), or concerns about long-term safety of topical rapamycin in a pediatric population could significantly set back the program.